News

News
Announcement
Avero Diagnostics and VitaDX announce the signing of a strategic partnership for the distribution in the United States of VisioCyt® Bladder, a diagnostic test for bladder cancer
18 December 2023 -
CFU et Carrefour Pathologie
VitaDX at CFU and Carrefour Pathologie!
17 November 2023 -
Sowefund
Launch of the participatory financing campaign!
14 November 2023 -

It's official: the Sowefund crowdfunding campaign is now public and open to all!

VitaDX
VitaDX wins France2030's "Medical Imaging" call for projects!
18 October 2023 -
JT 20h TF1
VisioCyt® on TF1!
8 June 2023 -

A big thank you to the TF1 Group for this report broadcast on June 07, 2023 on the 8:00 pm news, showing the benefits of Artificial Intelligence…

VitaDX
Come and meet us !
2 January 2023 -

We will be present at several events in 2023. If you'd like to find out more about us and VisioCyt, our first innovative…

masterclass
Mltidisciplinary Masterclass dedicated to prostate and bladder cancers
8 July 2022 -

Multidisciplinary Masterclass organized by the American Hospital in Paris, MEDIPATH and Ibex Medical Analytics dedicated to prostate and bladder…

Medipath
VitaDX and MEDIPATH collaborate to deploy VisioCyt® , an innovative solution for the early diagnosis of bladder cancer
6 July 2022 -

VitaDX is proud to announce its partnership with Medipath, a group of independant pathologists specialized in locally based diagnostics and…

b&p
VitaDX is delighted to have been a part of the Bits & Pretzels HealthTech Conference!
29 June 2022 -

During the conference Bits & Pretzels HealthTech, Allan Rodriguez - CEO of VitaDX had the opportunity to participate in a panel discussion…